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This work focuses on pregnane X receptor (PXR) and its antagonists. PXR is a ligand-activated 
nuclear receptor that plays a major role in detoxification of xenobiotics and protecting the organism 
from their toxic effects. Recent evidence also shows endogenous action of PXR in the metabolism 
of lipids, glucose and bile acids. However, PXR activation could be harmful, since induction of 
biotransformation enzymes by PXR agonists may result in reduced treatment efficacy, increased 
toxicity of drug metabolites and resistance to chemotherapeutic agents. Recent research has been 
intensively focused on PXR antagonists capable of abolishing these unfavourable effects. Recently 
discovered human PXR antagonist SPA70 has a promising potential for future usage. In this study, 
we investigated the inhibitory effect of SPA70 on activated PXR. To activate PXR we used agonists 
binding directly to PXR (rifampicin, hyperforin, SR12813) and also agonists activating PXR 
indirectly via cell signalling pathways (U0126, PD184352, PD0325901). Experiments were 
performed using luciferase reporter gene assay in HepG2 cell line. Based on our results, we 
confirmed that SPA70 antagonizes agonist-activated PXR. We also presume that SPA70 inhibits 
activation of PXR caused by indirectly acting agonists. These findings provide a new insight into 
SPA70 antagonism and suggest another possible future application for the antagonist. 
